These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 37363815)
1. Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design. Venuto CS; Smith G; Herbst K; Zielinski R; Yung NCW; Grosset DG; Dorsey ER; Kieburtz K Mov Disord; 2023 Oct; 38(10):1774-1785. PubMed ID: 37363815 [TBL] [Abstract][Full Text] [Related]
2. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858 [TBL] [Abstract][Full Text] [Related]
3. Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks. ZhuParris A; Thijssen E; Elzinga WO; Makai-Bölöni S; Kraaij W; Groeneveld GJ; Doll RJ Mov Disord; 2023 Oct; 38(10):1795-1805. PubMed ID: 37401265 [TBL] [Abstract][Full Text] [Related]
4. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801 [TBL] [Abstract][Full Text] [Related]
5. The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease. Simonet C; Mahlknecht P; Marini K; Seppi K; Gill A; Bestwick JP; Lees AJ; Giovannoni G; Schrag A; Noyce AJ Mov Disord; 2023 Sep; 38(9):1636-1644. PubMed ID: 37317903 [TBL] [Abstract][Full Text] [Related]
6. Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease. Mirelman A; Volkov J; Salomon A; Gazit E; Nieuwboer A; Rochester L; Del Din S; Avanzino L; Pelosin E; Bloem BR; Della Croce U; Cereatti A; Thaler A; Roggen D; Mazza C; Shirvan J; Cedarbaum JM; Giladi N; Hausdorff JM Mov Disord; 2024 Feb; 39(2):328-338. PubMed ID: 38151859 [TBL] [Abstract][Full Text] [Related]
7. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT. Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100 [TBL] [Abstract][Full Text] [Related]
9. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716 [TBL] [Abstract][Full Text] [Related]
10. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort. Lawton M; Baig F; Toulson G; Morovat A; Evetts SG; Ben-Shlomo Y; Hu MT Mov Disord; 2020 Feb; 35(2):279-287. PubMed ID: 31693246 [TBL] [Abstract][Full Text] [Related]
11. The Impact of Type 2 Diabetes in Parkinson's Disease. Athauda D; Evans J; Wernick A; Virdi G; Choi ML; Lawton M; Vijiaratnam N; Girges C; Ben-Shlomo Y; Ismail K; Morris H; Grosset D; Foltynie T; Gandhi S Mov Disord; 2022 Aug; 37(8):1612-1623. PubMed ID: 35699244 [TBL] [Abstract][Full Text] [Related]
16. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P; BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448 [TBL] [Abstract][Full Text] [Related]
17. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Tan MMX; Lawton MA; Jabbari E; Reynolds RH; Iwaki H; Blauwendraat C; Kanavou S; Pollard MI; Hubbard L; Malek N; Grosset KA; Marrinan SL; Bajaj N; Barker RA; Burn DJ; Bresner C; Foltynie T; Wood NW; Williams-Gray CH; Hardy J; Nalls MA; Singleton AB; Williams NM; Ben-Shlomo Y; Hu MTM; Grosset DG; Shoai M; Morris HR Mov Disord; 2021 Feb; 36(2):424-433. PubMed ID: 33111402 [TBL] [Abstract][Full Text] [Related]
18. Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression. Lim SH; Ferdousi M; Kalteniece A; Mahfoud ZR; Petropoulos IN; Malik RA; Kobylecki C; Silverdale M Mov Disord; 2021 Aug; 36(8):1927-1934. PubMed ID: 33826165 [TBL] [Abstract][Full Text] [Related]
19. Motor progression trajectories and risk of mild cognitive impairment in Parkinson's disease: A latent class trajectory model from PPMI cohort. Chen X; He C; Ma J; Yang R; Qi Q; Gao Z; Du T; Zhang P; Li Y; Cai M; Zhang Y CNS Neurosci Ther; 2024 Aug; 30(8):e14918. PubMed ID: 39129413 [TBL] [Abstract][Full Text] [Related]
20. Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression. Christine CW; Auinger P; Saleh N; Tian M; Bottiglieri T; Arning E; Tran NK; Ueland PM; Green R; Mov Disord; 2020 Aug; 35(8):1466-1471. PubMed ID: 32407590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]